AU2020348382A1 - Methods of detecting neurological disorders via binding to phosphorylated tau protein - Google Patents

Methods of detecting neurological disorders via binding to phosphorylated tau protein Download PDF

Info

Publication number
AU2020348382A1
AU2020348382A1 AU2020348382A AU2020348382A AU2020348382A1 AU 2020348382 A1 AU2020348382 A1 AU 2020348382A1 AU 2020348382 A AU2020348382 A AU 2020348382A AU 2020348382 A AU2020348382 A AU 2020348382A AU 2020348382 A1 AU2020348382 A1 AU 2020348382A1
Authority
AU
Australia
Prior art keywords
carbons
alkyl
heterocycloalkyl
heteroarylene
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020348382A
Other languages
English (en)
Inventor
Suhail RASOOL
Stella SARRAF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amydis Inc
Original Assignee
Amydis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amydis Inc filed Critical Amydis Inc
Publication of AU2020348382A1 publication Critical patent/AU2020348382A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2020348382A 2019-09-18 2020-09-17 Methods of detecting neurological disorders via binding to phosphorylated tau protein Pending AU2020348382A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902265P 2019-09-18 2019-09-18
US62/902,265 2019-09-18
PCT/US2020/051325 WO2021055639A1 (en) 2019-09-18 2020-09-17 Methods of detecting neurological disorders via binding to phosphorylated tau protein

Publications (1)

Publication Number Publication Date
AU2020348382A1 true AU2020348382A1 (en) 2022-04-28

Family

ID=74883484

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020348382A Pending AU2020348382A1 (en) 2019-09-18 2020-09-17 Methods of detecting neurological disorders via binding to phosphorylated tau protein

Country Status (7)

Country Link
US (1) US20220370642A1 (cg-RX-API-DMAC7.html)
EP (1) EP4031879A4 (cg-RX-API-DMAC7.html)
JP (2) JP7591040B2 (cg-RX-API-DMAC7.html)
CN (1) CN114729945B (cg-RX-API-DMAC7.html)
AU (1) AU2020348382A1 (cg-RX-API-DMAC7.html)
CA (1) CA3154481A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021055639A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019279001B2 (en) 2018-05-31 2025-11-27 Amydis, Inc. Compositions and methods for detection of traumatic brain injury
US20250282723A1 (en) * 2021-06-16 2025-09-11 The Regents Of The University Of California Amyloid targeting agents and methods of using the same
US20240325572A1 (en) * 2021-07-15 2024-10-03 Amydis, Inc. N-heterocyclyl substituted 2-cyano-3-(naphthalen-2-yl)acrylamide derivatives as fluorophors for detection of amyloid and amyloid-like proteins for diagnosis of neurodegenerative disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102115429B (zh) * 2010-01-06 2013-02-27 中国科学院上海药物研究所 (e)-1-(3,5-二甲氧基苯基)-2-(3,5-二羟基-4-甲氧基苯基)乙烯及其制备方法和用途
CA2815960C (en) * 2010-10-29 2019-01-22 Clino Ltd. Tau imaging probe
CN106573880B (zh) * 2014-03-19 2019-07-30 阿米达斯公司 淀粉样蛋白靶向剂及其使用方法
EP3191107A2 (en) * 2014-09-12 2017-07-19 Amydis Diagnostics, Inc. In vitro compositions comprising human sample and amyloid targeting agent
JP7029718B2 (ja) * 2017-07-31 2022-03-04 国立研究開発法人量子科学技術研究開発機構 リン酸化タウタンパク質の測定方法
AU2019279001B2 (en) * 2018-05-31 2025-11-27 Amydis, Inc. Compositions and methods for detection of traumatic brain injury
AU2019372432B2 (en) * 2018-11-02 2025-05-29 Amydis, Inc. Phosphate compounds for detecting neurological disorders

Also Published As

Publication number Publication date
JP2024177285A (ja) 2024-12-19
EP4031879A1 (en) 2022-07-27
EP4031879A4 (en) 2023-11-15
CN114729945A (zh) 2022-07-08
US20220370642A1 (en) 2022-11-24
CN114729945B (zh) 2025-09-02
JP7591040B2 (ja) 2024-11-27
WO2021055639A1 (en) 2021-03-25
JP2022548158A (ja) 2022-11-16
CA3154481A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
AU2015231239B2 (en) Amyloid targeting agents and methods of using the same
JP2024177285A (ja) リン酸化タウタンパク質への結合を介した神経障害を検出する方法
AU2019372432B2 (en) Phosphate compounds for detecting neurological disorders
JP7583895B2 (ja) 外傷性脳損傷を検出するための組成物および方法
WO2023288109A1 (en) N-heterocyclyl substituted 2-cyano-3-(naphthalen-2-yl)acrylamide derivatives as fluorophors for detection of amyloid and amyloid-like proteins for diagnosis of neurodegenerative disorders
WO2024155678A1 (en) Amyloid targeting agents
WO2025117551A1 (en) Amino acid derivatives for detecting neurological disorders
HK40061967B (en) Phosphate compounds for detecting neurological disorders
HK40061967A (en) Phosphate compounds for detecting neurological disorders